Tham LS, Pantalone KM, Dungan K, et al. - Findings revealed that additional HbA1c and weight reductions can potentially be achieved by switching from semaglutide 0.5 mg to dulaglutide 3.0 or 4.5 mg with dose escalation; switching from semaglutide 1.0 mg to dulaglutide 4.5 mg could enhance weight loss.

• Exposure-response modelling was used to assess HbA1c and body weight alterations when semaglutide 0.5 mg or 1.0 mg once weekly (QW) is switched to dulaglutide 3.0 mg or 4.5 mg QW.

• HbA1c and body weight time-course models were created and validated, and simulations were performed for HbA1c and body weight over 52 weeks.

• From baseline, model-predicted mean alterations in HbA1c and weight at 26 weeks were up to -1.55% and -3.44 kg, respectively, for semaglutide 0.5 mg.

• At 52 weeks, further decreases were 0.19% and 1.40 kg, respectively, post-switching to dulaglutide 3.0 mg.

• For semaglutide 1.0 mg, predicted mean HbA1c and weight changes were -1.84% and -4.96 kg, respectively, at 26 weeks; post-switching to dulaglutide 4.5 mg, HbA1c was maintained with additional weight decrease of up to 0.57 kg at 52 weeks.

• Switching from semaglutide 1.0 mg to dulaglutide 3.0 mg led to preserved glycemic control.